@article{28c5d9ff3ad943808efacfbccaa8ec52,
title = "Mechanisms and funding opportunities in genitourinary cancer clinical research",
abstract = "Progress in the prevention, diagnosis, and treatment of genitourinary cancers is dependent on well-conducted clinical trials. The complexity and cost of clinical research continues to escalate, and success is dependent on adequate funding. Opportunities to fund such research include federal, industry, and private sources. The mechanisms whereby larger trials are conducted include contract research organizations, publically- and privately funded consortia, and the National Clinical Trials Network of the National Cancer Institute. The National Clinical Trials Network is the prime venue for investigators to conduct independent, phase III trials in the United States.",
keywords = "Clinical trials, Cooperative Groups, Funding, NCTN, Urologic cancers",
author = "Ryan, {Christopher W.}",
note = "Funding Information: The Genitourinary Committee of SWOG is well recognized for its successful conduct and reporting of important trials in urologic oncology. A key reason for its success is representation from specialists across disciplines, with active participation of Urologists and both Medical and Radiation Oncologists. Studies are multidisciplinary, including drug trials involving CTEP agents or sometimes directly secured from industry, surgical trials, and radiation trials. Translational medicine research is a component of most trials, and is funded by a variety of sources including federal (such as R01 or Biomarker, Imaging and Quality of Life Studies Funding Program) [15] , foundation, or industry sources. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2019",
month = may,
doi = "10.1016/j.urolonc.2018.05.024",
language = "English (US)",
volume = "37",
pages = "318--323",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",
}